Assisted Dying Revived?

Key Takeaways

• Parliament Act has been used only seven times, never for private bills
• Top‑ballot private member’s bills receive priority on limited Fridays
• Government time allocation is essential for the bill’s progress
• Lords’ opposition could trigger the Act, but only with Commons’ intent

Pulse Analysis

The Terminally Ill Adults (End of Life) Bill resurfaced as Parliament reconvenes, prompting advocates to consider the 1911 Parliament Act as a shortcut around the House of Lords. Historically, the Act has been a rare tool, deployed in just seven instances—primarily to override Lords’ objections on government bills. Its untested application to a private member’s bill introduces legal uncertainty, but it also offers a constitutional mechanism for the elected Commons to assert its legislative will when faced with persistent upper‑chamber resistance.

The practical path forward hinges on the private member’s ballot scheduled for 21 May. MPs who land in the top twenty secure a guaranteed slot on one of seven Fridays reserved for private legislation, dramatically increasing their chances of advancing a proposal. However, even a top‑ballot MP lacks control over parliamentary time; without ministerial allocation for debates and procedural motions, the bill could stall despite Commons support. Government neutrality on assisted dying further complicates matters, as active facilitation might be interpreted as policy endorsement, while inaction could be seen as obstructing the Commons’ constitutional primacy.

Should the Lords reject the bill again, the Speaker could certify that the statutory conditions for the Parliament Act are met, allowing royal assent before the session ends. This scenario would not only legalise assisted dying in England and Wales but also set a precedent for future private legislation to bypass the Lords, reshaping the balance of power within Westminster. Stakeholders—from healthcare providers to civil‑rights groups—must watch the procedural dance closely, as the outcome will influence both end‑of‑life policy and the broader dynamics of UK legislative authority.